The Parkinson's disease therapy developer completed a series A round featuring QB3-aligned Mission Bay Capital.
Nitrome Biosciences, a US-based developer of treatments for age-related disorders, has secured $38m in a series A round backed by Mission Bay Capital, the VC arm of University of California-aligned commercialisation office California Institute for Quantitative Biosciences.
AbbVie Ventures, the corporate venturing arm of pharmaceutical firm AbbVie, and VC firm Sofinnova Partners co-led the round, which also included Alexandria Venture Investments, the VC arm of life sciences real estate investment trust Alexandria Real Estate Equities, and Dementia Discovery Fund.
Nitrome will put the series A funds into progressing its lead drug candidate, a potential Parkinson’s disease treatment, toward its first clinical proof of concept studies in human subjects.
The company’s approach targets a type of enzyme called nitrases and it intends to explore the expansion of its drug development platform to other age-related disorders, such as neurodegenerative diseases, type 2 diabetes, cancer and heart disease.
…
